Premenstrual Dysphoric Disorder - Pipeline Insight, 2024

Premenstrual Dysphoric Disorder - Pipeline Insight, 2024

DelveInsight’s, “Premenstrual Dysphoric Disorder (PMDD) – Pipeline Insight, 2024,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Premenstrual Dysphoric Disorder (PMDD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Premenstrual Dysphoric Disorder (PMDD) Understanding

Premenstrual Dysphoric Disorder (PMDD): Overview

Premenstrual dysphoric disorder (PMDD) is similar to premenstrual syndrome (PMS) that occurs due to the changes in the hormone levels right a week or two before the start of the period. It been established that the hormone levels tend to fall after ovulation resulting in PMDD. The exact cause of this condition isn’t known yet. It affects about 5% women of childbearing age.

Symptoms

Symptoms of PMDD include feelings of anxiety and tension, panic attacks, lasting anger or irritability that may affect others, tiredness or low energy, mood swings, feelings of despair, sadness, and suicidal thoughts, trouble sleeping, binge eating, losing interest in daily life and relationships, and physical symptoms, such as breast tenderness, bloating, muscle or joint pain, and headaches.

Diagnosis

For the diagnosis of PMDD, a complete physical and pelvic exam is conducted along with thorough medical history. As most of the symptoms associated with this disease are related to mental health, the diagnosis may also be made based on those where mental health-related symptoms during the menstrual cycle are observed and listed over several months.

Treatment

Treatment of PMDD becomes quite imperative as it can severely affect the quality of life. Some of the ways to treat PMDD are birth control pills, changes in lifestyle, selective serotonin reuptake inhibitors, stress management, anti-inflammatory medicines, and vitamin supplements

Premenstrual Dysphoric Disorder (PMDD) Emerging Drugs Chapters

This segment of the Premenstrual Dysphoric Disorder (PMDD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Premenstrual Dysphoric Disorder (PMDD) Emerging Drugs

• UC-1010: Asarina Pharma

UC-1010, also known as Sepranolone, is in the Phase II stage of drug development. It belongs to the class of antidepressants and work as GABA-A receptor antagonists. The company completed the Phase IIB trial for PMDD in October 2020 in four countries.

Further product details are provided in the report……..

Premenstrual Dysphoric Disorder (PMDD): Therapeutic Assessment

This segment of the report provides insights about the different Premenstrual Dysphoric Disorder (PMDD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Premenstrual Dysphoric Disorder (PMDD)

There are approx. 2+ key companies which are developing the therapies for Premenstrual Dysphoric Disorder (PMDD). The companies which have their Premenstrual Dysphoric Disorder (PMDD) drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Asarina Pharma and others.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Premenstrual Dysphoric Disorder (PMDD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Premenstrual Dysphoric Disorder (PMDD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Premenstrual Dysphoric Disorder (PMDD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Premenstrual Dysphoric Disorder (PMDD) drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Premenstrual Dysphoric Disorder (PMDD) R&D. The therapies under development are focused on novel approaches to treat/improve Premenstrual Dysphoric Disorder (PMDD).

Premenstrual Dysphoric Disorder (PMDD) Report Insights

• Premenstrual Dysphoric Disorder (PMDD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Premenstrual Dysphoric Disorder (PMDD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Premenstrual Dysphoric Disorder (PMDD) drugs?
• How many Premenstrual Dysphoric Disorder (PMDD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Premenstrual Dysphoric Disorder (PMDD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Premenstrual Dysphoric Disorder (PMDD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Premenstrual Dysphoric Disorder (PMDD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Asarina Pharma

Key Products

• UC-1010